More on Albany Molecular Research's (AMRI) Q1: Contract revenue and margins rise 9% and 19% Y/Y...


More on Albany Molecular Research's (AMRI) Q1: Contract revenue and margins rise 9% and 19% Y/Y respectively with the latter driven by improvements in the performance of the discovery and large scale manufacturing segments. The company reaffirms its FY13 revenue guidance (~12% growth) and ups its EPS outlook to $0.52-0.65 per share. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs